165 related articles for article (PubMed ID: 29169282)
1. Efficacy of buparlisib in treating breast cancer.
Robert M; Frenel JS; Bourbouloux E; Berton Rigaud D; Patsouris A; Augereau P; Gourmelon C; Campone M
Expert Opin Pharmacother; 2017 Dec; 18(18):2007-2016. PubMed ID: 29169282
[TBL] [Abstract][Full Text] [Related]
2. Buparlisib in breast cancer.
Sirohi B; Rastogi S; Dawood S
Future Oncol; 2015; 11(10):1463-70. PubMed ID: 25963424
[TBL] [Abstract][Full Text] [Related]
3. Buparlisib , an oral pan-PI3K inhibitor for the treatment of breast cancer.
Geuna E; Milani A; Martinello R; Aversa C; Valabrega G; Scaltriti M; Montemurro F
Expert Opin Investig Drugs; 2015 Mar; 24(3):421-31. PubMed ID: 25645727
[TBL] [Abstract][Full Text] [Related]
4. Benefits versus risk profile of buparlisib for the treatment of breast cancer.
Patsouris A; Augereau P; Frenel JS; Robert M; Gourmelon C; Bourbouloux E; Berton-Rigaud D; Chevalier LM; Campone M
Expert Opin Drug Saf; 2019 Jul; 18(7):553-562. PubMed ID: 31159599
[No Abstract] [Full Text] [Related]
5. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Di Leo A; Johnston S; Lee KS; Ciruelos E; Lønning PE; Janni W; O'Regan R; Mouret-Reynier MA; Kalev D; Egle D; Csőszi T; Bordonaro R; Decker T; Tjan-Heijnen VCG; Blau S; Schirone A; Weber D; El-Hashimy M; Dharan B; Sellami D; Bachelot T
Lancet Oncol; 2018 Jan; 19(1):87-100. PubMed ID: 29223745
[TBL] [Abstract][Full Text] [Related]
6. PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer.
Guerin M; Rezai K; Isambert N; Campone M; Autret A; Pakradouni J; Provansal M; Camerlo J; Sabatier R; Bertucci F; Charafe-Jauffret E; Hervieu A; Extra JM; Viens P; Lokiec F; Boher JM; Gonçalves A
Eur J Cancer; 2017 Nov; 86():28-36. PubMed ID: 28950146
[TBL] [Abstract][Full Text] [Related]
7. 5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.
Beaufils F; Cmiljanovic N; Cmiljanovic V; Bohnacker T; Melone A; Marone R; Jackson E; Zhang X; Sele A; Borsari C; Mestan J; Hebeisen P; Hillmann P; Giese B; Zvelebil M; Fabbro D; Williams RL; Rageot D; Wymann MP
J Med Chem; 2017 Sep; 60(17):7524-7538. PubMed ID: 28829592
[TBL] [Abstract][Full Text] [Related]
8. A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer.
McRee AJ; Marcom PK; Moore DT; Zamboni WC; Kornblum ZA; Hu Z; Phipps R; Anders CK; Reeder-Hayes K; Carey LA; Weck KE; Perou CM; Dees EC
Clin Breast Cancer; 2018 Aug; 18(4):289-297. PubMed ID: 29153866
[TBL] [Abstract][Full Text] [Related]
9. Phase I Study of the Pan-PI3K Inhibitor Buparlisib in Adult Chinese Patients with Advanced Solid Tumors.
Wu YL; Zhang LI; Trandafir L; Dong T; Duval V; Hazell K; Xu B
Anticancer Res; 2016 Nov; 36(11):6185-6194. PubMed ID: 27793950
[TBL] [Abstract][Full Text] [Related]
10. Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy.
Saura C; Bendell J; Jerusalem G; Su S; Ru Q; De Buck S; Mills D; Ruquet S; Bosch A; Urruticoechea A; Beck JT; Di Tomaso E; Sternberg DW; Massacesi C; Hirawat S; Dirix L; Baselga J
Clin Cancer Res; 2014 Apr; 20(7):1935-45. PubMed ID: 24470511
[TBL] [Abstract][Full Text] [Related]
11. Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations.
Bardia A; Gounder M; Rodon J; Janku F; Lolkema MP; Stephenson JJ; Bedard PL; Schuler M; Sessa C; LoRusso P; Thomas M; Maacke H; Evans H; Sun Y; Tan DSW
Oncologist; 2020 Jan; 25(1):e160-e169. PubMed ID: 31395751
[TBL] [Abstract][Full Text] [Related]
12. Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?
Zardavas D; Fumagalli D; Loi S
Curr Opin Oncol; 2012 Nov; 24(6):623-34. PubMed ID: 22960556
[TBL] [Abstract][Full Text] [Related]
13. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
Beck JT; Ismail A; Tolomeo C
Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
[TBL] [Abstract][Full Text] [Related]
14. PI3K/Akt/mTOR Intracellular Pathway and Breast Cancer: Factors, Mechanism and Regulation.
Sharma VR; Gupta GK; Sharma AK; Batra N; Sharma DK; Joshi A; Sharma AK
Curr Pharm Des; 2017; 23(11):1633-1638. PubMed ID: 27848885
[TBL] [Abstract][Full Text] [Related]
15. Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.
Wen PY; Touat M; Alexander BM; Mellinghoff IK; Ramkissoon S; McCluskey CS; Pelton K; Haidar S; Basu SS; Gaffey SC; Brown LE; Martinez-Ledesma JE; Wu S; Kim J; Wei W; Park MA; Huse JT; Kuhn JG; Rinne ML; Colman H; Agar NYR; Omuro AM; DeAngelis LM; Gilbert MR; de Groot JF; Cloughesy TF; Chi AS; Roberts TM; Zhao JJ; Lee EQ; Nayak L; Heath JR; Horky LL; Batchelor TT; Beroukhim R; Chang SM; Ligon AH; Dunn IF; Koul D; Young GS; Prados MD; Reardon DA; Yung WKA; Ligon KL
J Clin Oncol; 2019 Mar; 37(9):741-750. PubMed ID: 30715997
[TBL] [Abstract][Full Text] [Related]
16. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
[TBL] [Abstract][Full Text] [Related]
17. Inhibiting the PI3K signaling pathway: buparlisib as a new targeted option in breast carcinoma.
Estévez LG; García E; Hidalgo M
Clin Transl Oncol; 2016 Jun; 18(6):541-9. PubMed ID: 26510854
[TBL] [Abstract][Full Text] [Related]
18. A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma.
McPherson V; Reardon B; Bhayankara A; Scott SN; Boyd ME; Garcia-Grossman IR; Regazzi AM; McCoy AS; Kim PH; Al-Ahmadie H; Ostrovnaya I; Roth AJ; Farooki A; Berger MF; Rosenberg JE; Solit DB; Van Allen E; Milowsky MI; Bajorin DF; Iyer G
Cancer; 2020 Oct; 126(20):4532-4544. PubMed ID: 32767682
[TBL] [Abstract][Full Text] [Related]
19. Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2.
Campone M; Im SA; Iwata H; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Cortés J; De Laurentiis M; Arteaga CL; Jiang Z; Jonat W; Le Mouhaër S; Sankaran B; Bourdeau L; El-Hashimy M; Sellami D; Baselga J
Eur J Cancer; 2018 Nov; 103():147-154. PubMed ID: 30241001
[TBL] [Abstract][Full Text] [Related]
20. A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.
Ma CX; Luo J; Naughton M; Ademuyiwa F; Suresh R; Griffith M; Griffith OL; Skidmore ZL; Spies NC; Ramu A; Trani L; Pluard T; Nagaraj G; Thomas S; Guo Z; Hoog J; Han J; Mardis E; Lockhart C; Ellis MJ
Clin Cancer Res; 2016 Apr; 22(7):1583-91. PubMed ID: 26563128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
